Tyrosine Kinase Inhibitors Used Alone or in Combination to Treat RCC

Early nivolumab responders sustained years-long treatment-free survival after treatment discontinuation.

Durable outcomes were reported standard-dose tivozanib monotherapy in second- and third-line metastatic RCC.

Darlifarnib plus cabozantinib showed durable responses and manageable safety in cabozantinib-naive advanced clear cell RCC.

A post-hoc analysis of LITESPARK-005 found that higher baseline and improved on-treatment QOL scores tracked with lower risk of disease progression and death.

The FDA issued final guidances on performance status, washout periods, and laboratory values aimed at expanding oncology trial participation.